Qingdao Vland Biotech INC.

SHSE:603739 주식 보고서

시가총액: CN¥3.5b

Qingdao Vland Biotech 과거 수익 실적

과거 기준 확인 0/6

Qingdao Vland Biotech's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 8.1% per year. Qingdao Vland Biotech's return on equity is 5.2%, and it has net margins of 5.2%.

주요 정보

-6.3%

수익 성장률

-10.1%

EPS 성장률

Biotechs 산업 성장11.3%
매출 성장률8.1%
자기자본 수익률5.2%
순이익5.2%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

May 06
Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

Recent updates

Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding

Sep 05
Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding

Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%

Jun 07
Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%

Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

May 06
Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings

Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks

Apr 16
Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks

수익 및 비용 분석

Qingdao Vland Biotech 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SHSE:603739 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 241,26566341111
30 Jun 241,26479338114
31 Mar 241,25383340115
31 Dec 231,19981327111
30 Sep 231,21371324111
30 Jun 231,17564321104
31 Mar 231,14062308101
31 Dec 221,16370309102
30 Sep 221,1489230099
30 Jun 221,134109288104
31 Mar 221,141122292103
31 Dec 211,151133291101
30 Sep 211,10013027596
30 Jun 211,07812628191
31 Mar 211,03011627686
31 Dec 2096010926480
30 Sep 2092210328274
30 Jun 208848927875
31 Mar 208708927274
31 Dec 198477826975
30 Sep 198407925378
30 Jun 198248123573
31 Mar 198088422970
31 Dec 188148322770
30 Sep 1880586396121
31 Dec 177998623371
31 Dec 167818324077
31 Dec 157527022783
31 Dec 14728533360

양질의 수익: 603739 has a large one-off gain of CN¥24.5M impacting its last 12 months of financial results to 30th September, 2024.

이익 마진 증가: 603739's current net profit margins (5.2%) are lower than last year (5.8%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 603739's earnings have declined by 6.3% per year over the past 5 years.

성장 가속화: 603739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

수익 대 산업: 603739 had negative earnings growth (-6.7%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).


자기자본 수익률

높은 ROE: 603739's Return on Equity (5.2%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기